Clinical Trials
89 trialsGraft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
Ohio State University Comprehensive Cancer Center
Stem Cell Transplantation With NiCordĀ® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
City of Hope Medical Center
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
BRUOG-407
Brown University
REBOUND
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Masonic Cancer Center, University of Minnesota
Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)
Memorial Sloan Kettering Cancer Center
Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study
Mayo Clinic
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
National Cancer Institute (NCI)
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Celgene
EVAADE
Centre Leon Berard
UK-Haplo
University College, London
SARS-CoV-2 Donor-Recipient Immunity Transfer
City of Hope Medical Center
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
Ohio State University Comprehensive Cancer Center
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Sumitomo Pharma America, Inc.
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Fate Therapeutics
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Karyopharm Therapeutics Inc
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Opna Bio LLC
Pasireotide in Prevention of GI Toxicity
Duke University
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Northside Hospital, Inc.
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCordĀ® & UNM CBU to Patients With Hematological Malignancies
Gamida Cell ltd
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
Jazz Pharmaceuticals
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
National Cancer Institute (NCI)
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Icahn School of Medicine at Mount Sinai
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
Kiadis Pharma
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
Kiadis Pharma
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Novartis
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Dartmouth-Hitchcock Medical Center
ENESTnd
Novartis
Transplantation of NiCordĀ®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
Gamida Cell ltd
INSPIRE
Fred Hutchinson Cancer Center
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation
Memorial Sloan Kettering Cancer Center
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
M.D. Anderson Cancer Center
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
Mirror Biologics, Inc.
Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia
National Institutes of Health Clinical Center (CC)
GAH
Celgene
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
Regimmune Corporation
Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes
University of Utah
ALBUM
University of Arizona
Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])
Ann & Robert H Lurie Children's Hospital of Chicago
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
Agios Pharmaceuticals, Inc.
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers
National Institutes of Health Clinical Center (CC)
An Open-label Phase II Study of Lorvotuzumab Mertansine
M.D. Anderson Cancer Center